Precigen, Inc. is a commercial-stage biopharmaceutical company developing precision medicines for immuno-oncology, autoimmune disorders, and infectious diseases. The company leverages proprietary technology platforms, including the AdenoVerse immunotherapy platform and the UltraCAR-T platform, to construct gene programs that control expression levels and physiological location. Its approved product, Papzimeos (zopapogene imadenovec-drba), is a non-replicating adenoviral vector-based immunotherapy for the treatment of adults with recurrent respiratory papillomatosis. The clinical pipeline includes PRGN-2009, based on the AdenoVerse platform, and PRGN-3006, built on the UltraCAR-T platform, while PRGN-3005 and PRGN-3007 have paused enrollment. Precigen utilizes the UltraVector platform for DNA construction and the UltraPorator electroporation device to streamline the manufacturing of cell therapies. The company employs non-viral delivery systems, including the Sleeping Beauty transposon system and AttSite recombinases, to facilitate stable gene integration. It collaborates with the National Cancer Institute under a cooperative research and development agreement to advance PRGN-2009 in cervical and oropharyngeal cancers.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage precigen.com
Sector Healthcare IR page investors.precigen.com
Tags
gene therapy, cell therapy, immunotherapy, adenoviral vectors, electroporation, transposon systems, immuno-oncology, autoimmune disorders, infectious diseases, precision medicine, Papzimeos, zopapogene imadenovec-drba, PRGN-2012, PRGN-2009, PRGN-3005, PRGN-3006, PRGN-3007, AdenoVerse, UltraCAR-T, UltraPorator, UltraVector, Sleeping Beauty, AttSite, mbIL15
Press page —

Metrics

Valuation  
Market cap $ 3.069B
Market cap (USD) $ 3.069B
P/E 122.29
PEG —
P/BV 36.63
P/S 316.93
P/OCF -41.92
P/FCF -41.30
Dividend yield —
Turnover / mcap —
Returns  
ROE -843.6%
ROI -219.7%
ROIC -72.6%
Profit margin -2,588.2%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock —
Diluting (TTM) Yes
Debt/Equity 112.5%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 39
Quality score -62.5%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012
Revenue 9.684M 3.925M 6.225M 26.909M 103.873M 103.178M 90.722M 160.574M 230.981M 190.926M 173.605M 71.93M 23.76M 13.774M
Net profit -250.642M -126.235M -95.904M 28.317M -92.166M -170.521M -322.324M -509.336M -117.018M -186.612M -84.493M -81.822M -38.98M -81.874M
Free cash flow -89.826M -76.757M -68.466M -69.969M -63.018M -84.548M -173.81M -165.827M -150.805M -87.604M 22.92M -26.229M -55.21M -69.02M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012
Share price 4.18 1.12 1.34 1.52 3.71 10.2 5.48 6.54 11.52 24.3 30.15 27.53 23.8 —
Price performance 12m 2.73 -0.16 -0.12 -0.59 -0.64 0.86 -0.16 -0.43 -0.53 -0.19 0.1 0.16 — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 21.6M 19.8M 21.2M 20.7M 16.5M 20.8M 959,000 902,000 926,000 3.92M
↳ YoY growth -13.8% -8.6% +7.2% -2.6% -20.2% +26.4% -95.4% -5.9% +2.7% +322.9%
↳ 5y CAGR +168.8% +93.1% +7.2% -8.1% -0.8% -45.4% -46.8% -46.3% -25.0%
Borrowings, current (USD) 386,000 502,000 559,000 31.7M 360,000 402,000 43.2M 0.00 — —
Borrowings, non-current (USD) 7.56M 7.54M 211M 186M 172M 183M 0.00 — 0.00 93.2M
Lease liabilities (USD) — — 0.00 28M 10.4M 11.1M 8.2M 7.1M 5.5M 5.12M
Cash and deposits (USD) 62.6M 68.1M 103M 65.8M 51.8M 42.9M 4.86M 7.58M 29.5M 30.2M
Intangible assets (USD) 226M 233M 129M 68.3M 65.4M 54.1M 44.5M 40.7M 4.46M 3.18M
Right-of-use assets (USD) — — 0.00 25.2M 9.35M 10.9M 8.09M 7.1M 5.06M 4.68M
Net debt (borrowings + leases - cash) (USD) -54.7M -60.1M 109M 180M 130M 151M 46.6M -481,000 -24M 68.1M
Cash flow detail
Operating cash flow (USD) -56M -104M -124M -136M -77M -55.8M -65M -66.9M -68.2M -87.8M
Purchases of property, plant and equipment (USD) -31.6M -46.7M -41.6M -37.9M -7.53M -7.25M -4.92M -1.54M -8.58M -2M
Change in receivables (cash effect) (USD) 2.59M 740,000 -2.7M -262,000 2.21M -6.18M -2.23M 76,000 -24,000 -2.99M
Change in inventories (cash effect) (USD) 3.81M 663,000 -478,000 4.1M 2.51M -1.9M 2.34M 0.00 0.00 -9.21M
Change in payables (cash effect) (USD) 3.62M -3.4M 4.68M — — — — — — —
Interest paid (cash effect) (USD) -964,000 -617,000 -3.87M -3.75M -7.2M -7.16M -8.54M -1.17M -7,000 -3.51M
Income taxes paid (cash effect) (USD) -10,000 -566,000 -216,000 -50,000 -48,000 -36,000 0.00 -21,000 -4,000 -3,000
Share-based compensation (USD) 42.2M 41.6M 36.3M 19M 18.4M 13.9M 10.2M 9.89M 9.47M 10.9M
Operating cash flow before change in receivables (USD) -58.6M -105M -122M -136M -79.2M -49.6M -62.8M -67M -68.1M -84.8M
Free cash flow (OCF - PPE - intangibles) (USD) -87.6M -151M -166M -174M -84.5M -63M -70M -68.5M -76.8M -89.8M
Income detail
Research and development expense (USD) 112M 143M 405M — — — — 48.6M 53.1M 41.3M
↳ 5y CAGR +9.8% +17.5% +53.1% -34.5%
Total comprehensive income (USD) -214M -106M -528M -323M -139M -96M 24.6M -94.4M -124M -251M
Comprehensive income to owners (USD) -210M -96.4M -522M -321M -139M -96M 24.6M -94.4M -124M -430M
Provision for credit losses (USD) 1.96M 1.22M 1.78M 3.24M 899,000 1.27M 944,000 0.00 0.00 —
Credit cost ratio (credit losses / average receivables) (%) 8.4% 5.9% 8.7% 15.5% 4.8% 6.8% 8.7% 0.0% 0.0% —
Reported Mar 1, 2017 Mar 1, 2018 May 9, 2019 Mar 2, 2020 Mar 1, 2021 Mar 1, 2022 Mar 6, 2023 Mar 25, 2026 Mar 25, 2026 Mar 25, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Nov 04, 2026

Download PDF

  • PAPZIMEOS® net revenue rose 37% quarter-over-quarter to $72.9 million in the third quarter of 2026 bringing launch-to-date net product revenue to $151 million, underscoring sustained commercial momentum and expanding US adoption

  • Achieved positive cash flow in the third quarter of 2026, a full quarter ahead of guidance, driven by robust PAPZIMEOS uptake

  • Net income for the third quarter of $35.8 million

  • Cash, cash equivalents, and investments totaled $51.0 million as of September 30, 2026

  • Received FDA Platform Technology Designation for the AdenoVerse® platform, creating opportunities to expedite development of current and future therapies

  • New long-term follow-up data presented at AAO-HNSF 2026 demonstrated ongoing durable complete responses after PAPZIMEOS treatment for up to five years

  • Conference call scheduled for 4:30 PM ET today

GERMANTOWN, Md., Nov. 4, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced third quarter 2026 financial results and business updates.

Precigen Logo

"Precigen has established an exceptional position of strength, with commercial momentum and a proven strategy driving our next phase of growth," said Helen Sabzevari, PhD, President and CEO of Precigen. "PAPZIMEOS has transformed treatment for adults with RRP, with well over 500 patients initiating treatment and 300 of them having completed treatment demonstrating recognition as the first-line standard of care. Its compelling value proposition is supported by an unmatched 51% complete response rate, ongoing durable complete responses up to five years, a well-characterized safety profile, and straightforward administration without a specialized device. PAPZIMEOS also received full FDA approval without the need for a confirmatory trial. Strong commercial uptake has driven sequential revenue growth and positive cash flow ahead of guidance, putting us well on our way to realizing its blockbuster potential. We are actively advancing a comprehensive lifecycle strategy to unlock the full potential of PAPZIMEOS with ongoing redosing clinical trial, pediatric development, and geographic expansion activities. PAPZIMEOS has established a powerful foundation for our next chapter, and the FDA's Platform Technology Designation positions us to realize the broader potential of AdenoVerse to advance our portfolio."

"PAPZIMEOS net revenue grew 37% quarter-over-quarter to $72.9 million, demonstrating the strength of our commercial execution and growing demand for the first FDA-approved therapy for adults with RRP," said Phil Tennant, Chief Commercial Officer of Precigen. "As of today, well over 500 patients have begun PAPZIMEOS treatment and over 300 of them have completed treatment. Physicians are increasingly making PAPZIMEOS their treatment of choice, driven by its compelling efficacy, safety and long-term durability. We have established a commanding first-mover advantage, supported by broad payer coverage, a permanent J-code and a straightforward treatment experience, with subcutaneous administration that requires no specialized devices. With a substantial addressable patient population, we continue to build on this momentum as we deepen adoption, expand patient access and capitalize on PAPZIMEOS as the preferred first-line treatment for adults with RRP."

"PAPZIMEOS has fundamentally transformed how we treat adults with RRP, establishing a new first-line standard of care for a disease that, for more than a century, was managed primarily through repeated surgeries. The potential for durable freedom from surgery, combined with demonstrated clinical efficacy, a well-characterized safety profile, and straightforward subcutaneous administration, represents a remarkable advance for our patients," said Dr. Clark A. Rosen, Lewis Francis Morrison, MD Endowed Chair in Laryngology, Professor, Department of Otolaryngology – Head and Neck Cancer Center, Chief, Division of Laryngology, Co-Director, UCSF Voice and Swallowing Center, University of California, San Francisco. "We are moving beyond simply managing the recurrence of disease to a treatment approach that offers the possibility of sustained disease control."

KEY PLATFORM AND PROGRAM HIGHLIGHTS

AdenoVerse®Platform Technology DesignationIn September 2026, Precigen announced that the US Food and Drug Administration (FDA) granted Platform Technology Designation to its AdenoVerse immunotherapeutic platform, building on the successful FDA approval of PAPZIMEOS, the first AdenoVerse-based therapy. The designation recognizes the platform's potential to be applied across multiple therapies and creates opportunities to expedite development of current and future AdenoVerse-based candidates by leveraging existing manufacturing and preclinical data, reducing duplicative development efforts, and enabling earlier and more frequent engagement with the FDA.

PAPZIMEOS®: First-line Standard of Care for the Treatment of Adults with RRPPAPZIMEOS (zopapogene imadenovec-drba) is the first FDA-approved therapy for adults with recurrent respiratory papillomatosis (RRP). PAPZIMEOS is a non-replicating adenoviral vector-based immunotherapy designed to generate an immune response directed against HPV 6 and HPV 11 proteins in patients with RRP.

  • Full approval with unmatched efficacy: PAPZIMEOS received full FDA approval in August 2025, with a broad label and without the requirement for a post-approval confirmatory clinical trial to verify clinical benefit. In its pivotal clinical study, PAPZIMEOS demonstrated a 51% complete response rate (18 of 35 patients), defined as no surgeries during the 12 months following treatment completion. This primary efficacy result, reflected in its FDA-approved prescribing information, established a new clinical benchmark in RRP.

  • Established safety profile and straightforward administration: In the pivotal clinical study, PAPZIMEOS demonstrated a well-characterized safety profile, with no dose-limiting toxicities or treatment-related adverse events greater than Grade 2 reported. PAPZIMEOS is administered subcutaneously without the need for an external specialized administration device, supporting adoption across a broad range of clinical settings.

  • Unmatched durability: Updated long-term follow-up data presented at the 2026 American Academy of Otolaryngology–Head and Neck Surgery Foundation (AAO-HNSF) Annual Meeting demonstrated sustained ongoing complete responses following PAPZIMEOS treatment for up to five years. Responses remain ongoing, and follow-up continues.

  • Preferred first-line treatment: PAPZIMEOS has become the first-line standard of care treatment for adult RRP patients. An independent expert consensus paper sponsored by the Recurrent Respiratory Papillomatosis Foundation (RRPF) and authored by 16 leading RRP physicians recommends PAPZIMEOS as the preferred first-line treatment and it is widely recognized as the new standard of care.

  • Significant first-mover advantage: As the first FDA-approved therapy for adults with RRP, PAPZIMEOS has established a significant first-mover advantage, supported by broad commercial access and growing adoption across major centers, a network of infusion centers and community practices.

  • Strong commercial adoption: Within just over one year following FDA approval, well over 500 patients have initiated treatment with PAPZIMEOS, with well over 300 of them completing treatment. Rapid adoption across academic and community settings, including among patients with fewer than three surgeries in the preceding year, demonstrates strong physician uptake across the spectrum of RRP disease severity.

  • Broad payer coverage and streamlined reimbursement: PAPZIMEOS has payer coverage across over 315 million US lives through private health plans, Medicare and Medicaid, representing nearly 100% of insured lives nationwide. The permanent J-code, J3404, effective April 1, 2026, provides a standardized reimbursement pathway, supporting efficient claims processing and facilitating broader institutional adoption.

  • Redosing study enrolling patients: Enrollment in the Company's open-label study to evaluate redosing efficacy of zopapogene imadenovec in adults with RRP is ongoing (clinical trial identifier: NCT06538480). The goal of the study is to provide an opportunity for the partial responders to become complete responders.

  • MAA under review by the EMA: The European Medicines Agency (EMA) has validated and is reviewing the Marketing Authorization Application (MAA) submitted in November 2025 for zopapogene imadenovec for the treatment of adults with RRP. PAPZIMEOS has been granted orphan drug designation from the European Commission.

PRGN-2009 AdenoVerse**®****Immunotherapy in HPV-associated Diseases**PRGN-2009 is an investigational AdenoVerse immunotherapy designed to activate the immune system to recognize and target HPV-associated diseases.

  • PRGN-2009 Phase 2 clinical trials under a cooperative research and development agreement (CRADA) with the National Cancer Institute (NCI) in newly diagnosed HPV-associated oropharyngeal cancer are ongoing.

  • A multicenter Phase 2 clinical trial of PRGN-2009 in combination with pembrolizumab in recurrent/metastatic cervical cancer is ongoing.

  • The Company plans to present new Phase 2 clinical data from its PRGN-2009 program in newly diagnosed HPV-associated oropharyngeal cancer at a forthcoming R&D Day, together with a comprehensive update on PRGN-2009 and its broader AdenoVerse development strategy.

FINANCIAL RESULTS

"The third quarter marked another significant financial milestone for Precigen," said Harry Thomasian Jr., Chief Financial Officer of Precigen. "PAPZIMEOS net revenue grew 37% quarter-over-quarter to $72.9 million, driving net income of $35.8 million, or $0.08 per diluted share. We previously guided to positive cash flow by the end of the year, and we are pleased to have achieved it a full quarter ahead of that guidance, with net cash provided by operating activities of $11.9 million. These results reflect strong PAPZIMEOS uptake and our disciplined approach to spending. These results are particularly remarkable given that PAPZIMEOS launched just one year ago, and we expect continued revenue momentum as adoption grows while we maintain our focus on fiscal responsibility."

Third Quarter 2026 Financial Results Compared to Prior Year PeriodTotal revenues were $74.1 million for the three months ended September 30, 2026, an increase of $71.2 million compared to the three months ended September 30, 2025. The significant increase in total revenues was primarily due to the recording of commercial sales of PAPZIMEOS following its FDA approval in August 2025. Net product revenues from PAPZIMEOS for the three months ended September 30, 2026 were $72.9 million. No PAPZIMEOS sales were recorded for the three months ended September 30, 2025. The increase in total revenues was partially offset by a $1.8 million decrease in collaboration and licensing revenue.

Cost of product and services increased by $5.5 million, or greater than 500%, compared to the three months ended September 30, 2025, primarily due to costs related to the commercial sale of PAPZIMEOS following its FDA approval in August 2025. These costs include the cost of product sold as well as other production-related costs that do not meet the criteria for capitalization as inventory. Prior to regulatory approval, costs associated with the production of PAPZIMEOS were expensed as research and development in accordance with the Company's accounting policy.

R&D expenses decreased by $5.7 million, or 46.4%, compared to the three months ended September 30, 2025, primarily due to the change in the accounting treatment of PAPZIMEOS manufacturing costs. Prior to the FDA approval of PAPZIMEOS in August 2025, costs associated with the manufacturing of PAPZIMEOS were expensed as R&D. Following the FDA approval and the commencement of commercial sales, these production costs are no longer expensed as research and development but are capitalized as inventory on the balance sheet and recognized as cost of product and services as the product is sold. The decrease also reflects lower performance-based compensation expense compared to the prior year period.

SG&A expenses decreased by $1.6 million, or 6.8%, compared to the three months ended September 30, 2025, primarily driven by lower performance-based compensation expense in the current year period. This decrease was offset by higher compensation and benefit expense related primarily to the expansion of the Company's workforce as well as increases in marketing and freight expenses, both driven by the commercial launch of PAPZIMEOS.

Total other expense, net decreased by $109.2 million, or 97.6% compared to the three months ended September 30, 2025, primarily attributable to the absence of a $111.5 million charge related to the increase in the fair value of warrant liabilities that was recorded in the prior-year period. This decrease was offset by an increase of $2.1 million in interest expense related to long-term debt entered into in the third quarter of 2025.

During the third quarter of 2025, the Company recorded a one-time $179.0 million non-cash deemed dividend on preferred stock as a reduction to additional paid-in capital (and an increase in net loss attributable to common shareholders when computing net loss per share) in accordance with Generally Accepted Accounting Principles ("GAAP"). On September 15, 2025, all of the then outstanding preferred shares were converted into common shares.

Net income was $35.8 million, or $0.10 per basic and $0.08 per diluted share for the three months ended September 30, 2026, compared to a net loss attributable to common shareholders of $325.3 million, or $1.06 per basic and diluted share, for the three months ended September 30, 2025.

First Nine Months 2026 Financial Results Compared to Prior Year PeriodTotal revenues were $152.4 million for the nine months ended September 30, 2026, an increase of $147.3 million compared to the nine months ended September 30, 2025. The significant increase in total revenues was primarily due to the recording of commercial sales of PAPZIMEOS following its FDA approval in August 2025. Revenues related to the sale of PAPZIMEOS for the nine months ended September 30, 2026 were $147.6 million. No PAPZIMEOS sales were recorded for the nine months ended September 30, 2025. Service revenue also increased $1.4 million, primarily due to higher revenue generated by the Company's Exemplar subsidiary.

Cost of product and services increased by $8.6 million, or greater than 250%, compared to the nine months ended September 30, 2025, primarily due to costs related to the commercial sale of PAPZIMEOS following its FDA approval in August 2025. These costs include the cost of product sold as well as other production-related costs that do not meet the criteria for capitalization as inventory. Prior to regulatory approval, costs associated with the production of PAPZIMEOS were expensed as research and development in accordance with the Company's accounting policy.

R&D expenses decreased by $14.8 million, or 43.1%, compared to the nine months ended September 30, 2025, primarily due to the change in the accounting treatment of PAPZIMEOS manufacturing costs. Prior to the FDA approval of PAPZIMEOS in August 2025, costs associated with the manufacturing of PAPZIMEOS were expensed as R&D, as regulatory approval and the probability of future economic benefit had not yet been established. Following the FDA approval and the commencement of commercial sales, these production costs are no longer expensed as research and development but are capitalized as inventory on the balance sheet and recognized as cost of product and services as the product is sold.

SG&A expenses increased by $13.2 million, or 25.1%, compared to the nine months ended September 30, 2025. This increase was primarily driven by commercial activities related to PAPZIMEOS following its FDA approval in August 2025. The higher expenses reflect increased costs to support commercialization, including third-party commercialization costs, freight expenses, expanded marketing and promotional activities to drive product awareness and adoption, and increased software subscription costs.

During the nine months ended September 30, 2025, the Company recorded a $3.9 million goodwill impairment charge related to the Company's Exemplar reporting unit with no comparable charge in the nine months ended September 30, 2026.

Total other expense, net decreased by $131.1 million, or 94.8%, compared to the nine months ended September 30, 2025, primarily attributable to the absence of a $139.5 million charge related to the increase in the fair value of warrant liabilities that was recorded in the prior-year period. The increase in warrant liabilities was mainly driven by a rise in the Company's common stock price and, to a lesser extent, by an increase in the liability for additional warrants that were expected at that point to be issued as paid-in-kind dividends on the Company's then outstanding Series A Preferred Stock. This decrease was offset by an increase of $8.0 million in interest expense related to long-term debt that was entered into in the third quarter of 2025.

During the nine months ended September 30, 2025, we recorded a one-time $179.0 million non-cash deemed dividend on preferred stock as a reduction to additional paid-in capital (and an increase in net loss attributable to common shareholders when computing net loss per share) in accordance with GAAP. On September 15, 2025, all of the then outstanding preferred shares were converted into common shares.

Net income was $47.9 million, or $0.13 per basic and $0.12 per diluted share for the nine months ended September 30, 2026, compared to a net loss attributable to common shareholders of $406.1 million, or $1.36 per basic and diluted share, for the nine months ended September 30, 2025.

Precigen: Advancing Medicine with Precision**®**Precigen (Nasdaq: PGEN) is a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to address difficult-to-treat diseases with high unmet patient need. Precigen is dedicated to advancing scientific breakthroughs from proof-of-concept through commercialization. With a strong commitment to innovation, Precigen is developing a robust pipeline of differentiated therapies across its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. For more information about Precigen, visit www.precigen.com or follow us on LinkedIn or YouTube.

TrademarksPrecigen, PAPZIMEOS, AdenoVerse, and Advancing Medicine with Precision are trademarks of Precigen and/or its affiliates. Other names may be trademarks of their respective owners.

Cautionary Statement Regarding Forward-Looking StatementsThis press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what the Company expects. Examples of forward-looking statements include, among others, information relating to the Company's business and business plans, the success of efforts to commercialize PAPZIMEOS® (zopapogene imadenovec-drba) for the treatment of recurrent respiratory papillomatosis (RRP) in adults including the revenue that the Company expects to realize from such efforts, the Company's ability to successfully obtain foreign regulatory approvals for PAPZIMEOS, expectations about the safety and efficacy of PAPZIMEOS, the ability of PAPZIMEOS to treat RRP, the Company's future financial and operational results including the Company's ability to reach or maintain quarterly profitability and positive cash flow, and the Company's ability to commence clinical studies or complete ongoing clinical studies for the Company's clinical and pre-clinical stage candidates. The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For further information on potential risks and uncertainties, and other important factors, any of which could cause the Company's actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in the Company's most recent Annual Report on Form 10-K and subsequent reports filed with the Securities and Exchange Commission.

**Investor Contact:**Steven M. Harasym Tel: +1 (202) 365-2563 [email protected]

**Media Contact:**Donelle M. Gregory [email protected]

| Precigen, Inc. and Subsidiaries Consolidated Balance Sheets (Unaudited) |

| (Amounts in thousands) | September 30, 2026 | | December 31, 2025 |

| Assets | | | |

| Current assets | | | |

| Cash and cash equivalents | $ 14,959 | | $ 30,234 |

| Short-term investments | 31,112 | | 67,624 |

| Receivables | | | |

| Trade, net | 96,486 | | 3,916 |

| Other | 133 | | 446 |

| Inventory | 22,915 | | 9,581 |

| Prepaid expenses and other | 6,157 | | 3,434 |

| Total current assets | 171,762 | | 115,235 |

| Long-term investments | 4,909 | | 2,511 |

| Property, plant and equipment, net | 13,295 | | 13,758 |

| Intangible assets, net | 2,227 | | 3,182 |

| Goodwill | 15,232 | | 15,232 |

| Right-of-use assets | 4,043 | | 4,679 |

| Other assets | 634 | | 908 |

| Total assets | $ 212,102 | | $ 155,505 |

| Liabilities and Shareholders' Equity | | | |

| Current liabilities | | | |

| Accounts payable | $ 7,056 | | $ 11,985 |

| Accrued compensation and benefits | 7,855 | | 10,199 |

| Other accrued liabilities | 14,568 | | 10,993 |

| Indemnification accruals | — | | 2,476 |

| Deferred revenue | 174 | | 517 |

| Current portion of lease liabilities | 1,135 | | 1,136 |

| Total current liabilities | 30,788 | | 37,306 |

| Long-term debt | 94,256 | | 93,174 |

| Lease liabilities, net of current portion | 3,216 | | 3,980 |

| Other long-term liabilities | 48 | | 134 |

| Total liabilities | 128,308 | | 134,594 |

| Shareholders' equity | | | |

| Additional paid-in capital | 2,377,321 | | 2,362,252 |

| Accumulated deficit | (2,293,440) | | (2,341,348) |

| Accumulated other comprehensive (loss) income | (87) | | 7 |

| Total shareholders' equity | 83,794 | | 20,911 |

| Total liabilities and shareholders' equity | $ 212,102 | | $ 155,505 |

| Precigen, Inc. and Subsidiaries Consolidated Statement of Operations (Unaudited) |

| (Amounts in thousands, except share | Three Months Ended September 30, | | Nine Months Ended September 30, |

| and per share data) | 2026 | | 2025 | | 2026 | | 2025 |

| Revenues | | | | | | | |

| Product revenues, net | $ 72,959 | | $ 162 | | $ 148,049 | | $ 406 |

| Service revenues | 1,189 | | 942 | | 4,329 | | 2,895 |

| Collaboration and licensing revenues | — | | 1,818 | | — | | 1,818 |

| Total revenues | 74,148 | | 2,922 | | 152,378 | | 5,119 |

| Operating Expenses | | | | | | | |

| Cost of products and services | 6,508 | | 1,035 | | 11,872 | | 3,227 |

| Research and development | 6,631 | | 12,377 | | 19,551 | | 34,343 |

| Selling, general and administrative | 22,359 | | 23,991 | | 65,657 | | 52,483 |

| Impairment of goodwill | — | | — | | — | | 3,907 |

| Total operating expenses | 35,498 | | 37,403 | | 97,080 | | 93,960 |

| Operating income (loss) | 38,650 | | (34,481) | | 55,298 | | (88,841) |

| Other Income (Expense), Net | | | | | | | |

| Change in fair value of warrant liabilities | — | | (111,502) | | — | | (139,523) |

| Interest expense | (2,996) | | (902) | | (8,857) | | (903) |

| Interest income | 323 | | 534 | | 1,372 | | 2,148 |

| Other income (expense), net | (11) | | 7 | | 295 | | (17) |

| Total other expense, net | (2,684) | | (111,863) | | (7,190) | | (138,295) |

| Income (loss) before income taxes | 35,966 | | (146,344) | | 48,108 | | (227,136) |

| Income tax expense | (200) | | — | | (200) | | (3) |

| Net income (loss) | $ 35,766 | | $ (146,344) | | $ 47,908 | | $ (227,139) |

| Deemed dividends on preferred stock | — | | (179,000) | | — | | (179,000) |

| Net income (loss) attributable to common shareholders | $ 35,766 | | $ (325,344) | | $ 47,908 | | $ (406,139) |

| Net income (loss) per share | | | | | | | |

| Net income (loss) per share, basic | $ 0.10 | | $ (1.06) | | $ 0.13 | | $ (1.36) |

| Net income (loss) per share, diluted | $ 0.08 | | $ (1.06) | | $ 0.12 | | $ (1.36) |

| Weighted average shares outstanding, basic | 358,249,260 | | 307,170,490 | | 356,492,444 | | 299,210,344 |

| Weighted average shares outstanding, diluted | 421,162,494 | | 307,170,490 | | 415,432,302 | | 299,210,344 |

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/precigen-reports-third-quarter-2026-results-highlighted-by-strong-sequential-papzimeos-revenue-growth-and-positive-cash-flow-ahead-of-guidance-302929690.html

SOURCE Precigen, Inc.

Company Logo

Privacy Preference Center

Your Opt Out Preference Signal is Honored

Privacy Preference Center

  • Your Privacy

  • Strictly Necessary Cookies

  • Functional Cookies

  • Performance & Analytics Cookies

  • Targeting & Advertising Cookies

Your Privacy

When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences or your device and is mostly used to make the site work as you expect it to. The information does not usually directly identify you, but it can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to find out more and change our default settings. However, blocking some types of cookies may impact your experience of the site and the services we are able to offer.

Strictly Necessary Cookies

Always Active

These cookies are necessary for the website to function as intended and cannot be switched off. You can configure your browser to block these cookies, but doing so may cause parts of the website to stop functioning properly and will impact your user experience with our Services. These cookies do not store any personally identifiable information.

Cookie Details

Functional Cookies

Functional Cookies Active

These cookies enable the website to provide enhanced functionality and personalization like, for example, remembering your preferences and username. They may be set by us or by third party providers whose services we have integrated and utilize.

Performance & Analytics Cookies

Performance & Analytics Cookies Active

These cookies allow us to understand how users interact with our website and Services so that we can evaluate and improve performance. For example, their use allows us to count visits and traffic sources so we can measure and improve the performance of our site and help us to understand how users move around the site. All information these cookies collect is aggregated and anonymous.

Cookie Details

Targeting & Advertising Cookies

Targeting & Advertising Cookies Active

These cookies may be set through our website by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant advertisements on other sites. They operate by uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.

Cookie Details

Cookie List

Leg.Interest

checkbox label label

checkbox label label

checkbox label label

Clear

  • checkbox label label

Apply Cancel

Reject All Cookies Accept All Cookies

Powered by Onetrust

Oct 28, 2026

Download PDF

GERMANTOWN, Md., Oct. 28, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced the Company will release third quarter 2026 financial results and provide business updates on Wednesday, November 4, 2026. The Company will host a conference call to discuss results that day at 4:30 PM ET.

The conference call may be accessed by dialing 1-800-836-8184 (North America) or 1-646-357-8785 (International). Participants are asked to dial in 10-15 minutes in advance of the scheduled call time to facilitate timely connection to the call.

Event details can be found on Precigen's website in the Events & Presentations section at investors.precigen.com/events-presentations.

Precigen: Advancing Medicine with Precision**®**Precigen (Nasdaq: PGEN) is a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to address difficult-to-treat diseases with high unmet patient need. Precigen is dedicated to advancing scientific breakthroughs from proof-of-concept through commercialization. With a strong commitment to innovation, Precigen is developing a robust pipeline of differentiated therapies across its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. For more information about Precigen, visit www.precigen.com or follow us on LinkedIn or YouTube.

Cautionary Statement Regarding Forward-Looking StatementsThis press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what the Company expects. Examples of forward-looking statements include, among others, information relating to the Company's business and business plans, the success of efforts to commercialize PAPZIMEOS**®** (zopapogene imadenovec-drba) for the treatment of recurrent respiratory papillomatosis (RRP) in adults including the revenue that the Company expects to realize from such efforts, the Company's ability to successfully obtain foreign regulatory approvals for PAPZIMEOS, expectations about the safety and efficacy of PAPZIMEOS, the ability of PAPZIMEOS to treat RRP, the Company's future financial and operational results including the Company's ability to reach cash flow break-even, and the Company's ability to commence clinical studies or complete ongoing clinical studies for the Company's clinical and pre-clinical stage candidates. The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For further information on potential risks and uncertainties, and other important factors, any of which could cause the Company's actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in the Company's most recent Annual Report on Form 10-K and subsequent reports filed with the Securities and Exchange Commission.

**Investor Contact:**Steven M. Harasym Tel: +1 (202) 365-2563 [email protected]

**Media Contact:**Donelle M. Gregory [email protected]

Cision View original content:https://www.prnewswire.com/news-releases/precigen-to-announce-third-quarter-2026-financial-results-and-provide-business-updates-on-november-4-302921419.html

SOURCE Precigen, Inc.

Company Logo

Privacy Preference Center

Your Opt Out Preference Signal is Honored

Privacy Preference Center

  • Your Privacy

  • Strictly Necessary Cookies

  • Functional Cookies

  • Performance & Analytics Cookies

  • Targeting & Advertising Cookies

Your Privacy

When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences or your device and is mostly used to make the site work as you expect it to. The information does not usually directly identify you, but it can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to find out more and change our default settings. However, blocking some types of cookies may impact your experience of the site and the services we are able to offer.

Strictly Necessary Cookies

Always Active

These cookies are necessary for the website to function as intended and cannot be switched off. You can configure your browser to block these cookies, but doing so may cause parts of the website to stop functioning properly and will impact your user experience with our Services. These cookies do not store any personally identifiable information.

Cookie Details

Functional Cookies

Functional Cookies Active

These cookies enable the website to provide enhanced functionality and personalization like, for example, remembering your preferences and username. They may be set by us or by third party providers whose services we have integrated and utilize.

Performance & Analytics Cookies

Performance & Analytics Cookies Active

These cookies allow us to understand how users interact with our website and Services so that we can evaluate and improve performance. For example, their use allows us to count visits and traffic sources so we can measure and improve the performance of our site and help us to understand how users move around the site. All information these cookies collect is aggregated and anonymous.

Cookie Details

Targeting & Advertising Cookies

Targeting & Advertising Cookies Active

These cookies may be set through our website by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant advertisements on other sites. They operate by uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.

Cookie Details

Cookie List

Leg.Interest

checkbox label label

checkbox label label

checkbox label label

Clear

  • checkbox label label

Apply Cancel

Reject All Cookies Accept All Cookies

Powered by Onetrust

Sep 21, 2026

Download PDF

  • Designation has the potential to accelerate development of current and future therapies built on Precigen's AdenoVerse platform

GERMANTOWN, Md., Sept. 21, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced that the United States Food and Drug Administration (FDA) granted platform technology designation to the AdenoVerse® immunotherapeutic platform, which is used in the company's first commercial product, PAPZIMEOS®. The designation reflects the adaptability and potential of the platform to address a broad range of indications, including HPV-positive malignancies such as head and neck, cervical, anal, vulvar and vaginal cancers, as well as other diseases that may be targeted by future AdenoVerse-based product candidates.

Precigen Logo

FDA platform technology designation creates a pathway to leverage data generated for the development of PAPZIMEOS to potentially accelerate development of future AdenoVerse programs by utilizing existing manufacturing and preclinical knowledge to support future marketing applications and reduce duplication of development work. Platform technology designation provides opportunities for early FDA engagement, the ability to receive timely advice by having additional engagement with the FDA during development, and consideration of prior FDA manufacturing inspections for future applications.

To qualify for the platform technology designation, a platform must already be used in an FDA-approved product and the available evidence must demonstrate that it is well characterized, reproducible and has the potential to be adaptable across multiple products without compromising quality, manufacturing or safety. In granting this designation, the FDA determined that the AdenoVerse platform can be applied consistently across multiple products and is reasonably likely to generate meaningful efficiencies to the development or manufacturing process, and to the regulatory review process.

"This designation has the potential to accelerate the development of Precigen's broader AdenoVerse portfolio by allowing us to build on the technology established through PAPZIMEOS, which was approved by the FDA in August 2025. We expect the near-term impact will be especially meaningful for PRGN-2009 across multiple HPV-associated cancers, including cervical cancer and oropharyngeal squamous cell carcinoma. Importantly, the potential extends beyond PRGN-2009 to future AdenoVerse candidates such as those targeting additional cancers and other diseases," said Helen Sabzevari, PhD, President and CEO of Precigen. "We thank the FDA for recognizing the potential of the AdenoVerse platform. This designation will enable us to leverage prior data and engage with the FDA earlier and more frequently, creating opportunities to reduce duplicative work and bring greater speed, efficiency and predictability to the development of future AdenoVerse therapies."

AdenoVerse**®**Clinical Portfolio

Precigen's AdenoVerse portfolio includes a Phase 2 study of PRGN-2009 in combination with pembrolizumab in newly diagnosed patients with HPV-associated oropharyngeal squamous cell carcinoma (NCT05996523) and a Phase 2 study of PRGN-2009 in combination with pembrolizumab in patients with recurrent or metastatic cervical cancer (NCT06157151). The portfolio also includes PAPZIMEOS**®** (zopapogene imadenovec-drba; formerly PRGN-2012), which is the first FDA-approved therapy for the treatment of adults with recurrent respiratory papillomatosis (RRP). An open-label study evaluating the efficacy of redosing PAPZIMEOS in adults with RRP is currently enrolling (NCT06538480).

Precigen: Advancing Medicine with Precision**®**

Precigen (Nasdaq: PGEN) is a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to address difficult-to-treat diseases with high unmet patient need. Precigen is dedicated to advancing scientific breakthroughs from proof-of-concept through commercialization. With a strong commitment to innovation, Precigen is developing a robust pipeline of differentiated therapies across its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. For more information about Precigen, visit www.precigen.com or follow us on LinkedIn or YouTube.

Trademarks

Precigen, PAPZIMEOS, AdenoVerse, and Advancing Medicine with Precision are trademarks of Precigen and/or its affiliates. Other names may be trademarks of their respective owners.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what the Company expects. Examples of forward-looking statements include, among others, potential development efficiencies the platform technology designation may provide to accelerate the development of the Company's AdenoVerse clinical portfolio, potential benefits of the platform technology designation, information relating to the Company's business and business plans, the success of efforts to commercialize PAPZIMEOS® (zopapogene imadenovec-drba) for the treatment of recurrent respiratory papillomatosis (RRP) in adults, the Company's ability to successfully obtain foreign regulatory approvals for PAPZIMEOS, expectations about the safety and efficacy of PAPZIMEOS, the ability of PAPZIMEOS to treat RRP, the Company's future financial and operational results, and the Company's ability to commence clinical studies or complete ongoing clinical studies for the Company's clinical and pre-clinical stage candidates. The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For further information on potential risks and uncertainties, and other important factors, any of which could cause the Company's actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in the Company's most recent Annual Report on Form 10-K and subsequent reports filed with the Securities and Exchange Commission.

Investor Contact:

Steven M. Harasym Tel: +1 (202) 365-2563 [email protected]

Media Contact:

Donelle M. Gregory [email protected]

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/precigen-receives-fda-platform-technology-designation-for-adenoverse-platform-302884169.html

SOURCE Precigen, Inc.

Company Logo

Privacy Preference Center

Your Opt Out Preference Signal is Honored

Privacy Preference Center

  • Your Privacy

  • Strictly Necessary Cookies

  • Functional Cookies

  • Performance & Analytics Cookies

  • Targeting & Advertising Cookies

Your Privacy

When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences or your device and is mostly used to make the site work as you expect it to. The information does not usually directly identify you, but it can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to find out more and change our default settings. However, blocking some types of cookies may impact your experience of the site and the services we are able to offer.

Strictly Necessary Cookies

Always Active

These cookies are necessary for the website to function as intended and cannot be switched off. You can configure your browser to block these cookies, but doing so may cause parts of the website to stop functioning properly and will impact your user experience with our Services. These cookies do not store any personally identifiable information.

Cookie Details

Functional Cookies

Functional Cookies Active

These cookies enable the website to provide enhanced functionality and personalization like, for example, remembering your preferences and username. They may be set by us or by third party providers whose services we have integrated and utilize.

Performance & Analytics Cookies

Performance & Analytics Cookies Active

These cookies allow us to understand how users interact with our website and Services so that we can evaluate and improve performance. For example, their use allows us to count visits and traffic sources so we can measure and improve the performance of our site and help us to understand how users move around the site. All information these cookies collect is aggregated and anonymous.

Cookie Details

Targeting & Advertising Cookies

Targeting & Advertising Cookies Active

These cookies may be set through our website by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant advertisements on other sites. They operate by uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.

Cookie Details

Cookie List

Leg.Interest

checkbox label label

checkbox label label

checkbox label label

Clear

  • checkbox label label

Apply Cancel

Reject All Cookies Accept All Cookies

Powered by Onetrust

Prompts

Precigen, Inc. (ticker PGEN), listed in United States.

Company History

Date Change Detail
Feb 4, 2020 Renamed INTREXON CORP → PRECIGEN, INC.
May 10, 2017 Acquired Acquired Genvec Inc (CIK 934473). Its filings from before the deal are on its own company page, not shown here.

ETFs Holding Precigen, Inc.

ETF Weight in ETF Shares Market value As of
OASC 0.24% 32,950 $ 228.344K Aug 31, 2026
VFMO 0.13% 358,357 $ 2.483M Aug 31, 2026
RESM 0.03% 186 $ 1,060.20 Jun 30, 2026
MSSM 0.01% 12,398 $ 85.918K Aug 31, 2026
DXUV 0.01% 88,033 $ 410.234K Nov 12, 2026
DFAS 0.00% 264,449 $ 1.232M Nov 12, 2026
DFUS 0.00% 129,312 $ 602.594K Nov 12, 2026
DCOR 0.00% 150,551 $ 701.568K Nov 12, 2026
DFAC 0.00% 196,777 $ 916.981K Nov 12, 2026
DFAU 0.00% 2,101 $ 9,790.66 Nov 12, 2026
FESM 0.00% 333 $ 1,898.10 Jun 30, 2026